KRAS and neoplasm: Another approach involves DC-based vaccines, in which DCs are loaded with KRAS/RAS peptides to prime the immune system against cancer cells [132], leading to the activation of cytotoxic T cells and memory cells and thereby providing long-term surveillance against tumor recurrence [133].